StockWatch
·
Healthcare Research- Analytics & Technology
Board Meeting29 Apr 2026, 09:13 pm

Indegene Board Approves FY26 Results, Recommends ₹2.25 Dividend

AI Summary

Indegene Ltd's Board of Directors, at its meeting on April 29, 2026, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board also recommended a final dividend of ₹2.25 per equity share (face value ₹2/-) for the financial year 2025-26, which will be paid within 30 days of shareholder approval at the upcoming Annual General Meeting. Additionally, the Board approved allotments under the ESOP Scheme 2020 and RSU Scheme 2020, and sanctioned amendments to various policies under SEBI regulations, including those related to material subsidiaries, whistleblowers, insider trading, related party transactions, and corporate governance.

Key Highlights

  • Board approved audited financial results for Q4 and FY26.
  • Recommended a final dividend of ₹2.25 per equity share for FY26.
  • Approved allotment of shares under ESOP and RSU schemes.
  • Sanctioned amendments to multiple SEBI-mandated corporate policies.